MannKind (MNKD) Posts Q4 Loss of 66c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to MannKind (MNKD) Posts Q4 Loss of 66c/Share
March 14, 2016 4:48 PM EDT
VALENCIA, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) (TASE: MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2015.
For the fourth quarter of 2015, research and development expenses decreased 64.8%, from $17.6 million to $6.2 million, reflecting effects of our restructuring measures taken in 2015 and the transition from development to commercial activities. Â General and administrative costs declined 33.6%, from $12.5 million to $8.3 million, mainly due to a decrease in non-cash stock compensation expense. Â Sales of Afrezza continued to be lower than expected during the... More
March 14, 2016 4:00 PM EDT
VALENCIA, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) (TASE: MNKD) today announced that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts for Afrezza®, reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKinds executive leadership team.
Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. Â He joins MannKind from Amgen, Inc., where he spent over three... More
